As a trusted scientific partner to drug developers, Taconic works with researchers to identify fit-for-purpose models aligned with their therapeutic area, modality, translational requirements and stage of development. The collaboration with genOway builds on this expertise by adding new target-specific models to Taconic’s established portfolio and providing researchers with additional options for increasingly complex preclinical programs.
“Researchers rely on Taconic not only for access to high-quality animal models, but also for the scientific expertise to help identify the right model for the questions they need to answer,” said Mike Garrett, Chief Executive Officer of Taconic Biosciences. “Our partnership with genOway builds on that commitment, expanding the range of advanced humanized models we can offer U.S. researchers and helping drug developers make more informed model selections and generate data with greater translational relevance.”
The expanded portfolio will support research across therapeutic approaches including T-cell engagers and multispecifics, immune checkpoint and immunomodulatory therapies, Fc-mediated biologics, antibody-drug conjugates (ADCs), CAR-T therapies and other emerging modalities.
U.S. customers can work directly with Taconic to discuss model availability, cohort requirements, and ordering, anticipated delivery timing, therapeutic mechanism and model fit, and study-specific scientific considerations. Taconic’s scientific team can also help researchers identify potentially relevant models based on the human target, therapeutic mechanism and experimental question.
